For AML patients who are ineligible for standard treatment with chemotherapy and HSCT and who also experience less severe side effects, Laura Jimbu et al. propose that manipulation of both the co-inhibitory network (with anti-PD-L1 blocking antibodies) and suppressor network (with anti-IL-10 blocking antibodies) is an appealing immunotherapeutic intervention. Here, IL10 is linked to acute myeloid leukemia.